Arvinas, Inc (ARVN)
NASDAQ · Manufacturing · Pharmaceutical preparations
ARVN price, last 12 months
Key stats
- Previous close
- $7.79
- Open
- $7.78
- Day range
- $7.54 – $7.81
- 52-week range
- $6.97 – $14.51
- Volume
- 713.4K
- Avg volume (20 days)
- 865.5K
- Market cap
- $496.3M
Performance
Technicals and fundamentals
About Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $496.3M